Trial Outcomes & Findings for Injectable Diclofenac for the Prevention of Post-operative Dental Pain (NCT NCT01706588)
NCT ID: NCT01706588
Last Updated: 2014-09-05
Results Overview
Pain will be scored by the patient at the end of surgery (time 0) and at 15-minute intervals after surgery for a total of 6 hours on a 0-100 mm VAS (from 0 = no pain to 100 = worst pain imaginable).
COMPLETED
PHASE2
75 participants
Pain scores will be measured over the time from end of surgery (time 0) to the 6 hour post-surgery
2014-09-05
Participant Flow
Participant milestones
| Measure |
Diclofenac Sodium 5 mg/mL
Diclofenac sodium: One single diclofenac injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.
|
Diclofenac Sodium 12.5 mg/mL
Diclofenac sodium: One single diclofenac injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.
|
Diclofenac Sodium 25 mg/mL
Diclofenac sodium: One single diclofenac injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.
|
Diclofenac Sodium 50 mg/mL
Diclofenac sodium: One single diclofenac injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.
|
Placebo 1 mL
One single placebo injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.
|
|---|---|---|---|---|---|
|
Overall Study
STARTED
|
15
|
15
|
15
|
14
|
16
|
|
Overall Study
COMPLETED
|
15
|
15
|
15
|
14
|
16
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Injectable Diclofenac for the Prevention of Post-operative Dental Pain
Baseline characteristics by cohort
| Measure |
Diclofenac Sodium 5 mg/mL
n=15 Participants
Diclofenac sodium: One single diclofenac injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.
|
Diclofenac Sodium 12.5 mg/mL
n=15 Participants
Diclofenac sodium: One single diclofenac injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.
|
Diclofenac Sodium 25 mg/mL
n=15 Participants
Diclofenac sodium: One single diclofenac injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.
|
Diclofenac Sodium 50 mg/mL
n=14 Participants
Diclofenac sodium: One single diclofenac injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.
|
Placebo 1 mL
n=16 Participants
One single placebo injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.
|
Total
n=75 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|
|
Age, Continuous
|
28 years
STANDARD_DEVIATION 7.3 • n=5 Participants
|
28 years
STANDARD_DEVIATION 9.4 • n=7 Participants
|
30 years
STANDARD_DEVIATION 9 • n=5 Participants
|
27 years
STANDARD_DEVIATION 4.5 • n=4 Participants
|
30 years
STANDARD_DEVIATION 9.5 • n=21 Participants
|
28.6 years
STANDARD_DEVIATION 7.94 • n=8 Participants
|
|
Sex: Female, Male
Female
|
9 Participants
n=5 Participants
|
6 Participants
n=7 Participants
|
12 Participants
n=5 Participants
|
8 Participants
n=4 Participants
|
12 Participants
n=21 Participants
|
47 Participants
n=8 Participants
|
|
Sex: Female, Male
Male
|
6 Participants
n=5 Participants
|
9 Participants
n=7 Participants
|
3 Participants
n=5 Participants
|
6 Participants
n=4 Participants
|
4 Participants
n=21 Participants
|
28 Participants
n=8 Participants
|
PRIMARY outcome
Timeframe: Pain scores will be measured over the time from end of surgery (time 0) to the 6 hour post-surgeryPain will be scored by the patient at the end of surgery (time 0) and at 15-minute intervals after surgery for a total of 6 hours on a 0-100 mm VAS (from 0 = no pain to 100 = worst pain imaginable).
Outcome measures
| Measure |
Diclofenac Sodium 5 mg/mL
n=15 Participants
Diclofenac sodium: One single diclofenac injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.
|
Diclofenac Sodium 12.5 mg/mL
n=15 Participants
Diclofenac sodium: One single diclofenac injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.
|
Diclofenac Sodium 25 mg/mL
n=15 Participants
Diclofenac sodium: One single diclofenac injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.
|
Diclofenac Sodium 50 mg/mL
n=14 Participants
Diclofenac sodium: One single diclofenac injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.
|
Placebo 1 mL
n=16 Participants
One single placebo injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.
|
|---|---|---|---|---|---|
|
Area Under the Curve (AUC) of the Pain Scores.
|
6843 mm*minutes
Standard Deviation 6259
|
8832 mm*minutes
Standard Deviation 6330
|
9998 mm*minutes
Standard Deviation 8080
|
7290 mm*minutes
Standard Deviation 6509
|
15539 mm*minutes
Standard Deviation 9279
|
SECONDARY outcome
Timeframe: measured at 6 hours postsurgery, at day 3 and 1 week postsurgeryOutcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: measured at 6 hours postsurgery, at day 3 and 1 week postsurgeryOutcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: measured from end of surgery up to 12 hours postsurgeryOutcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: measured from end of surgery up to 1 week postsurgeryOutcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: consumed by the patient every 15-minutes postsurgery up to 6 hours postsurgeryOutcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: consumed by the patient from end of surgery up to 24 and up to 48 hours postsurgeryOutcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: at 6 hour postsurgery and on Day 3Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: measured from end of surgery up to 12 hours postsurgeryOutcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: at 6 hour postsurgery, and on day 3 and 1 week postsurgeryOutcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: every hour up to 6 hour postsurgeryOutcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: presurgery (within 30 days from surgery), at day of surgery (day 1), day 3 and 1 week postsurgery.Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: from signature of the informed consent to 1 week postsurgeryOutcome measures
Outcome data not reported
Adverse Events
Diclofenac Sodium 5 mg/mL
Diclofenac Sodium 12.5 mg/mL
Diclofenac Sodium 25 mg/mL
Diclofenac Sodium 50 mg/mL
Placebo 1 mL
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Diclofenac Sodium 5 mg/mL
n=15 participants at risk
Diclofenac sodium: One single diclofenac injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.
|
Diclofenac Sodium 12.5 mg/mL
n=15 participants at risk
Diclofenac sodium: One single diclofenac injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.
|
Diclofenac Sodium 25 mg/mL
n=15 participants at risk
Diclofenac sodium: One single diclofenac injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.
|
Diclofenac Sodium 50 mg/mL
n=14 participants at risk
Diclofenac sodium: One single diclofenac injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.
|
Placebo 1 mL
n=16 participants at risk
One single placebo injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.
|
|---|---|---|---|---|---|
|
Ear and labyrinth disorders
ear pain
|
13.3%
2/15 • Number of events 2
|
6.7%
1/15 • Number of events 1
|
0.00%
0/15
|
7.1%
1/14 • Number of events 1
|
0.00%
0/16
|
|
Gastrointestinal disorders
vomiting
|
13.3%
2/15 • Number of events 2
|
0.00%
0/15
|
13.3%
2/15 • Number of events 2
|
0.00%
0/14
|
6.2%
1/16 • Number of events 1
|
|
General disorders
injection site pain
|
13.3%
2/15 • Number of events 2
|
13.3%
2/15 • Number of events 2
|
26.7%
4/15 • Number of events 5
|
7.1%
1/14 • Number of events 1
|
0.00%
0/16
|
|
General disorders
swelling
|
6.7%
1/15 • Number of events 2
|
0.00%
0/15
|
0.00%
0/15
|
0.00%
0/14
|
0.00%
0/16
|
|
Nervous system disorders
headache
|
26.7%
4/15 • Number of events 4
|
0.00%
0/15
|
0.00%
0/15
|
7.1%
1/14 • Number of events 1
|
12.5%
2/16 • Number of events 4
|
|
Musculoskeletal and connective tissue disorders
pain in jaw
|
0.00%
0/15
|
26.7%
4/15 • Number of events 4
|
0.00%
0/15
|
0.00%
0/14
|
12.5%
2/16 • Number of events 2
|
|
Nervous system disorders
dizziness
|
0.00%
0/15
|
13.3%
2/15 • Number of events 2
|
0.00%
0/15
|
0.00%
0/14
|
0.00%
0/16
|
|
General disorders
injection site swelling
|
0.00%
0/15
|
0.00%
0/15
|
13.3%
2/15 • Number of events 2
|
0.00%
0/14
|
0.00%
0/16
|
|
Blood and lymphatic system disorders
linphadenopathy
|
0.00%
0/15
|
0.00%
0/15
|
0.00%
0/15
|
7.1%
1/14 • Number of events 1
|
0.00%
0/16
|
|
Gastrointestinal disorders
nausea
|
0.00%
0/15
|
0.00%
0/15
|
0.00%
0/15
|
7.1%
1/14 • Number of events 1
|
12.5%
2/16 • Number of events 2
|
|
Gastrointestinal disorders
gingival ulceration
|
0.00%
0/15
|
0.00%
0/15
|
0.00%
0/15
|
7.1%
1/14 • Number of events 1
|
0.00%
0/16
|
|
Injury, poisoning and procedural complications
procedural pain
|
0.00%
0/15
|
0.00%
0/15
|
0.00%
0/15
|
7.1%
1/14 • Number of events 1
|
0.00%
0/16
|
|
Nervous system disorders
lethargy
|
0.00%
0/15
|
0.00%
0/15
|
0.00%
0/15
|
7.1%
1/14 • Number of events 1
|
0.00%
0/16
|
|
Nervous system disorders
somnolence
|
0.00%
0/15
|
0.00%
0/15
|
0.00%
0/15
|
7.1%
1/14 • Number of events 1
|
0.00%
0/16
|
|
Respiratory, thoracic and mediastinal disorders
oropharyngeal pain
|
0.00%
0/15
|
0.00%
0/15
|
0.00%
0/15
|
7.1%
1/14 • Number of events 1
|
6.2%
1/16 • Number of events 1
|
|
Gastrointestinal disorders
diarrhoea
|
0.00%
0/15
|
0.00%
0/15
|
0.00%
0/15
|
0.00%
0/14
|
6.2%
1/16 • Number of events 1
|
|
Infections and infestations
wound infection
|
0.00%
0/15
|
0.00%
0/15
|
0.00%
0/15
|
0.00%
0/14
|
6.2%
1/16 • Number of events 1
|
|
Musculoskeletal and connective tissue disorders
joint stiffness
|
0.00%
0/15
|
0.00%
0/15
|
0.00%
0/15
|
0.00%
0/14
|
6.2%
1/16 • Number of events 1
|
|
Vascular disorders
hot flush
|
0.00%
0/15
|
0.00%
0/15
|
0.00%
0/15
|
0.00%
0/14
|
6.2%
1/16 • Number of events 1
|
Additional Information
Prof. Thomas Dietrich
The School of Dentistry, University of Birmingham
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: LTE60